Breast imaging developer Imaging Diagnostic Systems of Plantation, FL, is trying to get listed on the NASDAQ stock exchange, but it has run into difficulty due to the stock exchange's listing requirements. One of NASDAQ's requirements is that IDSI
Breast imaging developer Imaging Diagnostic Systems of Plantation, FL, is trying to get listed on the NASDAQ stock exchange, but it has run into difficulty due to the stock exchange's listing requirements. One of NASDAQ's requirements is that IDSI execute a reverse stock split to bring the company's share prices above $4; however, IDSI's board determined that a reverse split would be detrimental to shareholders. IDSI reported that it would appeal the NASDAQ's requirements and continue to seek the listing.
In other IDSI news, the company announced that it has signed an agreement with Imation that enables IDSI to sell Imation's DryView laser printers with its CT Laser Mammography system, when CTLM becomes commercially available. IDSI will also begin to market DryView in the U.S. directly and internationally through its distributors. IDSI added a distributor in Turkey with the signing of an agreement with Emtron, which will have rights to market CTLM in the country for 18 months.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.